Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fosun Kite Biotechnology Co. Ltd.
Headquarters: Shanghai, China
Website: http://www.fosunkitebio.com/...
Year Founded: 2017
Status: Archived
BioCentury | Sep 9, 2023
Deals
CAR T collaborations: the next cross-border deal trend?
BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
BioCentury | Sep 3, 2022
Regulation
Sept. 2 Quick Takes: Owkin receives EU approval for two AI-based cancer diagnostics
Plus FDA panel to discuss GSK’s anemia drug daprodustat, and updates from Neukio, Abivax and more
BioCentury | Jun 30, 2021
Deals
June 29 Quick Takes: $276M series C to enable Element to scale up sequencing tools; plus Yescarta, tislelizumab, Lynparza, Roche-4D, Actemra and more
Sequencing company Element Biosciences raised a $276 million in a series C round to advance its mission of providing lower cost, accessible DNA sequencing tools for research applications. The company
BioCentury | Apr 2, 2021
Product Development
Chinese biotechs look to next-generation CAR T technologies to solve market challenges
Chinese CAR T cell companies are mapping out solutions to their cost problem
Items per page:
1 - 6 of 6